Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases

Kidney International, Supplement

Volumn 63, Issue 85, 2003, Pages

  Boyce, Brendan F ^a   Xing, Lianping ^b   Shakespeare, William ^b   Wang, Yihan ^b   Dalgarno, David ^b   Iuliucci, John ^b   Sawyer, Tomi ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

Osteoblast; Osteoclast; RANKL; Src tyrosine kinase

Indexed keywords

AP 23451; FIBROBLAST GROWTH FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; UNCLASSIFIED DRUG;

APOPTOSIS; BONE CELL; BONE METASTASIS; BONE REMODELING; CELL ACTIVATION; CELL SURVIVAL; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DRUG DESIGN; DRUG TARGETING; FRACTURE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; STRUCTURE ACTIVITY RELATION;

EID: 0038188450     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.63.s85.2.x     Document Type: Conference Paper

References (32)

1. KARSENTY G, WAGNER EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2:389-406, 2002
2. SUDA T, TAKAHASHI N, UDAGAWA N, et al: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345-357, 1999
3. ERIKSEN EF: Normal and pathological remodeling of human trabecular bone: Three-dimensional reconstruction of the remodeling sequence in normal and in metabolic bone disease. Endocr Rev 7:379-408, 1986
4. EVERTS V, DELAISEE JM, KORPER W, et al: The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17:77-90, 2002
5. THEILL LE, BOYLE WJ, PENNINGER JM: RANK-L and RANK: T cells, bone loss, and mammalian evolution. Ann Rev Immunol 20:795-823, 2002
6. BEGG SK, BERTONCELLO I: The hematopoietic deficiencies in osteopetrotic (op/op) mice are not permanent, but progressively correct with age. Exp Hematol 21:493-495, 1993
7. TAKAHASHI N, UDAGAWA N, TAKAMI M, SUDA T: Cells of bone, osteoclast generation, in Principles of Bone Biology, edited by BILEZIKIAN PJ, RAISZ GL, RODAN AG, New York, Academic Press, Inc., 2002, pp 109-126
8. KONG YY, YOSHIDA H, SAROSI I, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999
9. TAKAYANAGI H, KIM S, KOGA T, et al: Induction and activation of the transcription factor NFATcl (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-890, 2002
10. CENCI S, WEITZMANN MN, ROGGIA C, et al: Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106:1229-1237, 2000
11. BOYCE BF, YONEDA T, LOWE C, et al: Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90:1622-1627, 1992
12. WONG B, BESSER D, KIM N, et al: TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4:1041-1049, 1999
13. XING L, VENEGAS AM, CHEN A, et al: Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 15:241-253, 2001
14. MANOLAGAS SC, KOUSTENI S, JILKA RL: Sex steroids and bone. Rec Prog Horm Res 57:385-409, 2002
15. BALDWIN A: The transcription factor NF-κB and human disease. J Clin Invest 107:3-6, 2001
16. MONTALBAN C, GARCIA-UNZUETA MT, DEFRANCISCO AL, AMADO JA: Serum interleukin-6 in renal osteodystrophy: Relationship with serum PTH and bone remodeling markers. Hormone Metab Res 31:4-7, 1999
17. DEMIGUEL F, MARTINEZ-FERNANDEZ P, GUILLEN C, et al: Parathyroid hormone-related protein stimulates interleukin-6 expression in human osteoblastic cells. J Am Soc Nephrol 10:796-803, 1999
18. HURLEY MM, MARIE P, FLORKIEWICZ R: Fibroblast growth factor (FGF) and FGF receptor families in bone, in Principles of Bone Biology, edited by BILEZIKIAN PJ, RAISZ GL, RODAN AG, New York, Academic Press, Inc., 2002, pp 825-851
19. HOCK JM, FITZPATRICK A, BILEZIKIAN JP: Action of parathyroid hormone, in Principles of Bone Biology, edited by BILEZIKIAN JP, RAISZ LG, RODAN GA, New York, Academic Press, Inc., 2002, pp 463-481
20. RUBIN MR, COSMAN F, LINDSAY R, BILEZIKIAN JP: The anabolic effects of parathyroid hormone. Osteoporosis Int 13:267-277, 2002
21. NEER RM, ARNAUD CD, ZANCHETTA JR, et al: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441, 2001
22. DEMPSTER DW, COSMAN F, KURLAND ES, et al: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16:1846-1853, 2001
23. JILKA RL, WEINSTEIN RS, BELLIDO T, et al: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446, 1999
24. KOUSTENI S, BELLIDO T, PLOTKIN LI, et al: Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730, 2001
25. DURIEUX S, MERCADAL L, ORCEL P, et al: Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation 74:496-500, 2002
26. KREAM EB, LUKERT PB: Clinical and basic aspects of glucocorticoid action in bone, in Principles of Bone Biology, edited by BILEZIKIAN PJ, RAISZ GL, RODAN AG, New York, Academic Press, Inc., 2002, pp 723-740
27. MARZIA M, SIMS NA, VOIT S, et al: Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320, 2000
28. SCHWARTZBERG PL: The many faces of Src: Multiple functions of a prototypical tyrosine kinase. Oncogene 17:1463-1468, 2000
29. BOYCE BF, XING L, BAIN S, et al: Novel bone-targeted Src tyrosine kinase inhibitors prevent bone loss and stimulate osteoblast activity. J Bone Miner Res 16(Suppl 1):S148, 2001
30. BOYCE BF, SHAKESPEARE W, XING L, WANG Y, et al: Development of a novel bone-targeted Src tyrosine kinase inhibitor AP23451 having potent in vitro and in vivo anti-resorptive properties for use in treating bone metastases and malignant hypercalcemia. J Bone Miner Res 17(Suppl 1):S159, 2002
31. XING LP, WANG Y, SUNDARAMOORTHI R, KEENAN T, et al: Discovery of novel dual action Src kinase inhibitors demonstrating anti-resorptive and bone formation activities in vitro and in vivo. J Bone Miner Res 17(Suppl 1):S377, 2002
32. NIJWEIDE PJ, BURGER EH, KLEIN-NULEND J: The osteocyte, in Principles of Bone Biology, edited by BILEZlKIAN JP, RAISZ LG, RODAN GA, New York, Academic Press. Inc., 2002, pp 93-107